glp-1 egfr cut off Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Repurposing Diabetes Therapies in CKD:

Oral GLP-1 medications deliver the appetite and metabolic benefits of GLP-1 therapy in a once-daily tablet instead of a weekly injection

Even if not meeting clinical hypoglycemia thresholds, some individuals may be sensitive to glucose fluctuations

In addition, increasing elimination of K through the gastrointestinal tract can be achieved with K binders

Research in animal models and population studies suggests GLP-1 receptor agonists may reduce dementia risk and improve cognitive function, but clinical trials are still ongoing

To bypass the pharmacological challenges associated with unspecific blocking of NMDA receptors, we designed a peptidedrug conjugate comprising the NMDA receptor antagonist MK-801 and a GLP-1 peptide analogue